BMC Cancer

Table 3 Associations between leptin, ObR, leptin/ObR and different clinicopathological parameters

From: Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivoanalysis

			Leptin		ObR
		N	Positive (%)	p-value	Positive (%)	p-value
*Diameter (mm)*				0.061		0.137
	≤ 10 mm	9	55.6		66.7
	> 10 mm	42	85.7		88.1
N				> 0.5		0.242
	N0	19	84.2		94.7
	N+ (N > 0)	33	78.8		81.8
*LVI*				> 0.5		0.473
	Negative	24	79.2		87.5
	Positive	27	77.8		77.8
*Menopausal status*				> 0.5		> 0.5
	Postmenopausal	15	80.0		86.7
	Premenopausal	39	82.1		84.6
*Histotype*				> 0.5		0.432
	Other	3	66.7		66.7
	Ductal (invasive)	45	80.0		84.4
	Inflammatory	4	100.0		100.0
	Intraductal	3	66.7		66.7
	Lobular (invasive)	4	75.0		75.0
G				0.495		0.366
	G1	7	85.7		100.0
	G2	18	88.9		88.9
	G3	26	73.1		76.9
*Ki-67*				> 0.5		> 0.5
	0–15%	33	75.8		81.8
	16–25%	9	88.9		88.9
	26–100%	14	85.7		85.7
*ER/PgR*				> 0.5		> 0.5
	ER-/PgR-	12	75.0		83.3
	ER-/PgR+	1	100.0		100.0
	ER+/PgR-	6	83.3		83.3
	ER+/PgR+	37	81.1		83.8
T				0.019		0.400
	pT1	20	70.0		80.0
	pT2	23	91.3		91.3
	pT3	2	0.0		50.0
	pT4	8	100.0		87.5
	pTx	1	100.0		100.0
	TIS	3	66.7		66.7
*HER2*				0.342		0.306
	Negative	28	85.7		89.3
	Positive	31	74.2		77.4

For each level of each clinicopathological variable, the total number (N) of patients is given together with the percentage of subjects positive for leptin or ObR expression. Abbreviations as in Tab. 2.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com